NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
NeoImmuneTech
Hoffmann-La Roche
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins